舌下含服粉尘螨滴剂治疗过敏性鼻炎患儿的临床效果及安全性分析

Clinical effect and safety analysis of subolingual dust mite drops in the treatment of allergic rhinitis in children

目的评估舌下含服粉尘螨滴剂应用在过敏性鼻炎(AR)患儿中的临床效果及安全性。方法纳入2021年1月—2022年1月的86例AR患儿,参照随机数字表法划分对照组(纳入43例,行常规抗过敏治疗)、观察组(纳入43例,行舌下含服粉尘螨滴剂治疗),评价组间症状积分、实验室指标、药物不良反应(ADR)。结果(1)治疗前,组间症状积分、实验室指标[免疫球蛋白E(IgE)、干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)]无差异,P>0.05;治疗4个月后,观察组症状积分、实验室指标(IgE、IFN-γ、IL-4)更佳,P<0.05;(2)在ADR方面,观察组(2.33%)与对照组(9.30%)无差异,P>0.05。结论对AR患儿行舌下含服粉尘螨滴剂治疗,安全性高,并且可以减轻炎症程度,减弱变态反应,促进症状消失,值得推广。

Objective To evaluate the clinical effect and safety of supraclingual dust mite drops in children with allergic rhinitis(AR).Methods A total of 86 children with AR from January 2021 to January 2022 were included,and divided into control group(43 cases included,receiving routine anti-allergy treatment)and observation group(43 cases included,receiving supraglingual treatment with dust mite drops)according to random number table method.Symptom scores,laboratory indexes,and adverse drug reactions(ADR)were evaluated between groups.Results(1)Before treatment,there were no differences in symptom scores,laboratory indexes[immunoglobulin E(IgE),interferon-γ(IFN-γ),interleukin-4(IL-4)]between groups,P>0.05;After 4 months of treatment,symptom scores,laboratory indexes(IgE,IFN-γ,IL-4)in the observation group were better,P<0.05;(2)There was no difference in ADR between the observation group(2.33%)and the control group(9.30%),P>0.05.Conclusion Subelingual treatment with mite dust drops in children with AR has high safety,and can reduce the degree of inflammation,reduce allergic reactions,and promote the disappearance of symptoms,which is worthy of promotion.